Drug Therapy, Combination

Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. Int J Chron Obstruct Pulmon Dis, 17, 1975-1986. http://doi.org/10.2147/copd.s378486
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Martinez, D., Lei, A., et al. (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133-141. http://doi.org/10.1080/15412555.2022.2045265